Boston Scientific Corp. (BSX): Price and Financial Metrics

Boston Scientific Corp. (BSX): $67.24

1.01 (+1.52%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

C

BSX Price/Volume Stats

Current price $67.24 52-week high $68.07
Prev. close $66.23 52-week low $47.51
Day low $66.16 Volume 5,833,600
Day high $67.43 Avg. volume 6,852,289
50-day MA $64.12 Dividend yield N/A
200-day MA $55.77 Market Cap 100.86B

BSX Stock Price Chart Interactive Chart >

BSX POWR Grades

  • BSX scores best on the Growth dimension, with a Growth rank ahead of 98.45% of US stocks.
  • The strongest trend for BSX is in Quality, which has been heading up over the past 26 weeks.
  • BSX ranks lowest in Momentum; there it ranks in the 24th percentile.

BSX Stock Summary

  • With a market capitalization of $84,383,007,955, BOSTON SCIENTIFIC CORP has a greater market value than 97.05% of US stocks.
  • BSX's current price/earnings ratio is 70.79, which is higher than 91.05% of US stocks with positive earnings.
  • In terms of volatility of its share price, BSX is more volatile than merely 1.09% of stocks we're observing.
  • Stocks that are quantitatively similar to BSX, based on their financial statements, market capitalization, and price volatility, are ZTS, BDX, SYK, ETN, and IDXX.
  • Visit BSX's SEC page to see the company's official filings. To visit the company's web site, go to www.bostonscientific.com.

BSX Valuation Summary

  • In comparison to the median Healthcare stock, BSX's price/sales ratio is 181.82% higher, now standing at 6.2.
  • Over the past 243 months, BSX's price/earnings ratio has gone up 4.1.

Below are key valuation metrics over time for BSX.

Stock Date P/S P/B P/E EV/EBIT
BSX 2023-12-29 6.2 4.5 71.0 43.3
BSX 2023-12-28 6.0 4.4 69.2 42.3
BSX 2023-12-27 6.0 4.3 68.8 42.1
BSX 2023-12-26 6.0 4.3 68.8 42.1
BSX 2023-12-22 6.0 4.3 68.7 42.0
BSX 2023-12-21 5.9 4.3 68.4 41.8

BSX Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 885.52%.
  • Its year over year cash and equivalents growth rate is now at -83.88%.
  • The year over year net income to common stockholders growth rate now stands at 275.12%.
Over the past 70 months, BSX's revenue has gone up $4.1e+09.

The table below shows BSX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 12,682 1,526 642
2022-09-30 12,567 1,197 597
2022-06-30 12,329 1,192 828
2022-03-31 12,162 1,528 754
2021-12-31 11,888 1,870 985
2021-09-30 11,470 2,065 1,100

BSX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BSX has a Quality Grade of C, ranking ahead of 73.14% of graded US stocks.
  • BSX's asset turnover comes in at 0.362 -- ranking 120th of 186 Medical Equipment stocks.
  • INGN, ECIA, and ATRC are the stocks whose asset turnover ratios are most correlated with BSX.

The table below shows BSX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.362 0.669 0.051
2021-03-31 0.328 0.649 0.032
2020-12-31 0.324 0.650 0.015
2020-09-30 0.331 0.672 0.003
2020-06-30 0.344 0.682 0.022
2020-03-31 0.386 0.704 0.043

BSX Price Target

For more insight on analysts targets of BSX, see our BSX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $51.08 Average Broker Recommendation 1.4 (Moderate Buy)

Boston Scientific Corp. (BSX) Company Bio


Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiologyinterventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiologycardiac surgeryvascular surgeryendoscopyoncologyurology and gynecology. (Source:Wikipedia)


BSX Latest News Stream


Event/Time News Detail
Loading, please wait...

BSX Latest Social Stream


Loading social stream, please wait...

View Full BSX Social Stream

Latest BSX News From Around the Web

Below are the latest news stories about BOSTON SCIENTIFIC CORP that investors may wish to consider to help them evaluate BSX as an investment opportunity.

Boston Sci sees Farapulse PFA receiving FDA approval in Q1

More on Boston Scientific

Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation (PFA) System* as a first-line treatment for persistent atrial fibrillation (AF), the only trial to study the use of PFA as frontline therapy in patients with this form of AF. Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to ou

Yahoo | December 28, 2023

3 Medical-Device Stocks Could Click in 2024

Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.

Yahoo | December 26, 2023

Show Me The Money: Inside Ken Griffin's Citadel's Jaw-Dropping $7 Billion Return

Citadel Founder and CEO Ken Griffin is one of the most successful investors of all time, managing over $62 billion in assets. He is also the founder of Citadel Securities, the largest market-making firm for the New York Stock Exchange and one of the largest designated market makers in the world. Citadel Securities is involved in one out of four stock trades placed in U.S. exchanges and nearly 40% of all retail trades. With a net worth of $37.5 billion, Griffin is one of the richest hedge fund ma

Yahoo | December 22, 2023

Insider Sell Alert: EVP Wendy Carruthers Sells 11,672 Shares of Boston Scientific Corp (BSX)

Boston Scientific Corp (NYSE:BSX), a leading innovator in medical solutions that improve the health of patients around the world, has recently witnessed a significant insider sell by one of its top executives.

Yahoo | December 19, 2023

Read More 'BSX' Stories Here

BSX Price Returns

1-mo 2.16%
3-mo 22.30%
6-mo 24.59%
1-year 37.70%
3-year 76.16%
5-year 76.25%
YTD 16.31%
2023 24.94%
2022 8.92%
2021 18.16%
2020 -20.50%
2019 27.96%

Continue Researching BSX

Want to see what other sources are saying about Boston Scientific Corp's financials and stock price? Try the links below:

Boston Scientific Corp (BSX) Stock Price | Nasdaq
Boston Scientific Corp (BSX) Stock Quote, History and News - Yahoo Finance
Boston Scientific Corp (BSX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!